The Fifth Department of Biological products, Institute of Medical Biology, Chinese Academy of Medical Science and Peking Union Medical College, Kunming, Yunnan Province, China.
The Department of Production Administration, Institute of Medical Biology, Chinese Academy of Medical Science and Peking Union Medical College, Kunming, Yunnan Province, China.
J Cell Mol Med. 2020 Oct;24(19):11198-11210. doi: 10.1111/jcmm.15672. Epub 2020 Sep 9.
We generated plasmid pools for the rapid preparation of candidate vaccine strains, which could grow in the Vero cells at low temperature. Firstly, we cloned in the pHW2000 plasmid each of the eight gene segments (PB2, PB1, PA, hemagglutinin [HA], neuraminidase [NA], NS, NP, M) of two master donor strains (MDS), respectively, A/Yunnan/1/2005Vca(H3N2) and B/Yunnan/2/2005Vca(By), which had Vca phenotype (cold-adapted phenotype in Vero cells). Secondly, the similar operation was implemented with each of the HA, NA and NP segments of circulating strains with epidemic potential (parental strains). The virus rescue techniques were employed in this study, according to the homology rate of HA segments between MDS and parental strains. Then, we harvested amount of new Vca virus strains. By transmission electron microscope, it could observe new viruses' diameter and length were from 100 to 120 nm. Importantly, these reassortant viruses could get high-yield production in Vero cells at 25℃ from the beginning to the fourth generation, which was significantly differ from their original parental viruses. Additional, these production 16 new Vca strains could maintain enough antibody binding capacity and attenuation phenotype, which consisted with their MDS. So these plasmid pools constructed by mount of different influenza A and B virus gene fragments could present desired working performance and provide convenience and realization for more Vca reassortant virus as candidate vaccine strain if needing.
我们生成了质粒池,用于快速制备候选疫苗株,这些疫苗株可以在低温下在 Vero 细胞中生长。首先,我们分别将两个主供体(MDS)菌株 A/Yunnan/1/2005Vca(H3N2)和 B/Yunnan/2/2005Vca(By)的 8 个基因片段(PB2、PB1、PA、血凝素[HA]、神经氨酸酶[NA]、NS、NP、M)克隆到 pHW2000 质粒中,这些 MDS 菌株具有 Vca 表型(在 Vero 细胞中具有冷适应表型)。其次,我们对具有流行潜力(亲本株)的循环株的 HA、NA 和 NP 片段进行了类似的操作。根据 MDS 和亲本株之间 HA 片段的同源率,本研究采用了病毒拯救技术。然后,我们收获了大量新的 Vca 病毒株。通过透射电子显微镜观察,新病毒的直径和长度在 100-120nm 之间。重要的是,这些重组病毒从第一代到第四代都可以在 25℃的 Vero 细胞中实现高产,这与它们原始的亲本病毒明显不同。此外,这些生产的 16 株新的 Vca 株能够保持足够的抗体结合能力和衰减表型,这与它们的 MDS 一致。因此,这些由大量不同的甲型和乙型流感病毒基因片段构建的质粒池可以表现出所需的工作性能,如果需要,为更多的 Vca 重组病毒作为候选疫苗株提供便利和实现。